CTSO at a glance
The past year
Chart+584.3% $4.37, close Nov 20
- From the highest close
- −31.8%
- Vs the 200-day average
- +164.6%
Short interest
History134,896 shares
- Since the last report
- +17.9%
- Days to cover
- 1.1 days
- Settled
- Oct 30, 2026
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 16 – Nov 22
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
CTSO price history
Loading recent earnings…
Investment thesis
What must happen next
Clinicians and hospitals continue to find Cytosorbents’ blood-purification approach useful in ICU and cardiac-surgery workflows, so demand behaves like recurring acute-care consumable utilization rather than fading trial demand.HoldingMateriality: High
FY2025 GAAP annual revenue was $37.063 million, up from $35.595 million in FY2024. If adoption persists, even a small company can compound revenue through recurring cartridge use; if protocols move away, the revenue base has little protection.
Watch: Critical-care or cardiac-surgery guideline committees decline to recommend hemoadsorption because trials fail to show sufficient patient benefit.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 GAAP annual revenue was $37.063 million, up from $35.595 million in FY2024.
Open source ↗The disposable medical-device model retains enough pricing power, mix benefit, and manufacturing efficiency to keep blood-purification sales structurally high margin despite small company scale.StrengtheningMateriality: High
FY2025 GAAP annual gross profit was $26.491 million on $37.063 million of revenue, implying an approximately 71.5% gross margin. High gross margins are the economic foundation for any eventual operating leverage; if tenders or competition compress pricing, growth would not translate into value.
Watch: European tenders, hospital purchasing groups, or distributors force lower cartridge prices to win volume.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 GAAP annual gross profit was $26.491 million on $37.063 million of revenue, implying an approximately 71.5% gross margin.
Open source ↗Management’s reduced spending base gives the business a credible path to operating leverage if adoption expands, rather than requiring revenue growth to be purchased with uncontrolled R&D and commercial expense.HoldingMateriality: Medium
FY2025 GAAP annual operating loss was $14.749 million, improved from a $16.452 million loss in FY2024. Owners need growth to become self-funding; if spending must re-accelerate just to defend the franchise, gross margin will not reach shareholders.
Watch: A new pivotal trial, post-market study, or FDA remediation program requires a major rebuild of R&D spending.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 GAAP annual operating loss was $14.749 million, improved from a $16.452 million loss in FY2024.
Open source ↗The company remains financing-dependent, so strategic capital, faster commercialization, or a sharp burn reduction is needed to prevent creditors or new equity from capturing too much of the upside.StrengtheningMateriality: Medium
Cash was $6.249 million at December 31, 2025. Even if the technology works, shareholders can lose if the company must raise capital on unfavorable terms before reaching scale.
Watch: A strategic partner, distributor, or acquirer provides non-dilutive capital or a meaningful upfront payment.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was $6.249 million at December 31, 2025.
Open source ↗The upside case depends on blood-purification use broadening beyond the current niche into larger cardiac-surgery or ICU protocols, because the existing revenue base is not yet large enough to absorb the public-company, regulatory, and commercial cost structure.HoldingMateriality: Medium
FY2025 GAAP net loss was $8.198 million despite $37.063 million of GAAP revenue. Without a larger addressable use case, CTSO may remain a high-gross-margin but structurally loss-making microcap device company.
Watch: FDA or other regulators reject, delay, or narrow a cardiac-surgery or antithrombotic-removal indication.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 GAAP net loss was $8.198 million despite $37.063 million of GAAP revenue.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Clinicians and hospitals continue to find Cytosorbents’ blood-purification approach useful in ICU and cardiac-surgery workflows, so demand behaves like recurring acute-care consumable utilization rather than fading trial demand. If adoption persists, even a small company can compound revenue through recurring cartridge use; if protocols move away, the revenue base has little protection.
The disposable medical-device model retains enough pricing power, mix benefit, and manufacturing efficiency to keep blood-purification sales structurally high margin despite small company scale. High gross margins are the economic foundation for any eventual operating leverage; if tenders or competition compress pricing, growth would not translate into value.
Management’s reduced spending base gives the business a credible path to operating leverage if adoption expands, rather than requiring revenue growth to be purchased with uncontrolled R&D and commercial expense. Owners need growth to become self-funding; if spending must re-accelerate just to defend the franchise, gross margin will not reach shareholders.
The company remains financing-dependent, so strategic capital, faster commercialization, or a sharp burn reduction is needed to prevent creditors or new equity from capturing too much of the upside. Even if the technology works, shareholders can lose if the company must raise capital on unfavorable terms before reaching scale.
The upside case depends on blood-purification use broadening beyond the current niche into larger cardiac-surgery or ICU protocols, because the existing revenue base is not yet large enough to absorb the public-company, regulatory, and commercial cost structure. Without a larger addressable use case, CTSO may remain a high-gross-margin but structurally loss-making microcap device company.
All standing thesis claims
Original report summary
ICU and cardiac-surgery adoption expands fast enough to outrun cash burn and financing risk.
Bull case and bear case
Bull case and bear case for Cytosorbents
Where the evidence on Cytosorbents stands: Holding on the latest evidence (Nov 22, 2026). Of its 5 thesis points, 2 strengthening and 3 holding.
Bull case: what the evidence supports
Clinicians and hospitals continue to find Cytosorbents’ blood-purification approach useful in ICU and cardiac-surgery workflows, so demand behaves like recurring acute-care consumable utilization rather than fading trial demand.
The disposable medical-device model retains enough pricing power, mix benefit, and manufacturing efficiency to keep blood-purification sales structurally high margin despite small company scale.
Management’s reduced spending base gives the business a credible path to operating leverage if adoption expands, rather than requiring revenue growth to be purchased with uncontrolled R&D and commercial expense.
The company remains financing-dependent, so strategic capital, faster commercialization, or a sharp burn reduction is needed to prevent creditors or new equity from capturing too much of the upside.
The upside case depends on blood-purification use broadening beyond the current niche into larger cardiac-surgery or ICU protocols, because the existing revenue base is not yet large enough to absorb the public-company, regulatory, and commercial cost structure.
Bear case: what would count against it
Critical-care or cardiac-surgery guideline committees decline to recommend hemoadsorption because trials fail to show sufficient patient benefit.
European tenders, hospital purchasing groups, or distributors force lower cartridge prices to win volume.
A new pivotal trial, post-market study, or FDA remediation program requires a major rebuild of R&D spending.
Thesis-Break Engine
What has broken in Cytosorbents’s thesis
Each break OptimistFi flagged on Cytosorbents, dated — with what has historically followed the same kind of break across the market, not a forecast for Cytosorbents.
- Late SEC filingcondition set before this filing
Across all companies, this kind of break has happened 4,811 times before. Those stocks trailed comparable companies by a median of 12% over the next six months, and 52% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedEntered a material definitive agreement.
Cytosorbents filed an SEC 8-K on 2026-11-20: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Cytosorbents filed an SEC 8-K on 2026-11-12: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedRegulation FD disclosure.
Cytosorbents filed an SEC 8-K on 2026-09-23: Regulation FD disclosure. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Critical-care or cardiac-surgery guideline committees decline to recommend hemoadsorption because trials fail to show sufficient patient benefit.
- European tenders, hospital purchasing groups, or distributors force lower cartridge prices to win volume.
- A new pivotal trial, post-market study, or FDA remediation program requires a major rebuild of R&D spending.
- A strategic partner, distributor, or acquirer provides non-dilutive capital or a meaningful upfront payment.
- FDA or other regulators reject, delay, or narrow a cardiac-surgery or antithrombotic-removal indication.
CTSO news
Loading headlines…
Financial statements
CTSO income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
CTSO: quick answers
- When does Cytosorbents (CTSO) report earnings next?
- Cytosorbents's next results are projected for February 4, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 12, 2026. Earnings calendar
- What is CTSO's short interest?
- As of October 30, 2026, 134,896 CTSO shares were sold short, up 17.9% from the count before. At the stock's average daily volume that is 1.1 days to cover. FINRA publishes the count twice a month. CTSO short interest history

